Clinical Trial Update: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A two-part open-label Phase Ib/II study evaluated varlitinib in combination with weekly paclitaxel for EGFR/HER2 co-expressing advanced or metastatic gastric ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Varlitinib (varlitinib)

Snippet

Sponsor: Yonsei University | Conditions: Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED